Literature DB >> 20593505

Thiopurine S-methyltransferase polymorphisms and thiopurine toxicity in treatment of inflammatory bowel disease.

Xian-Wen Dong1, Qing Zheng, Ming-Ming Zhu, Jing-Lu Tong, Zhi-Hua Ran.   

Abstract

AIM: To evaluate the relationship between thiopurine S-methyltransferase (TPMT) polymorphisms and thiopurine-induced adverse drug reactions (ADRs) in inflammatory bowel disease (IBD).
METHODS: Eligible articles that compared the frequency of TPMT polymorphisms among thiopurine-tolerant and -intolerant adult IBD patients were included. Statistical analysis was performed with Review Manager 5.0. Sub-analysis/sensitivity analysis was also performed.
RESULTS: Nine studies that investigated a total of 1309 participants met our inclusion criteria. The incidence of TPMT gene mutation was increased 2.93-fold (95% CI: 1.68-5.09, P = 0.0001) and 5.93-fold (95% CI: 2.96-11.88, P < 0.00001), respectively, in IBD patients with thiopurine-induced overall ADRs and bone marrow toxicity (BMT), compared with controls. The OR for TPMT gene mutation in IBD patients with thiopurine-induced hepatotoxicity and pancreatitis was 1.51 (95% CI: 0.54-4.19, P = 0.43) and 1.02 (95% CI: 0.26-3.99, P = 0.98) vs controls, respectively.
CONCLUSION: This meta-analysis suggests that the TPMT polymorphisms are associated with thiopurine-induced overall ADRs and BMT, but not with hepatotoxicity and pancreatitis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20593505      PMCID: PMC2896757          DOI: 10.3748/wjg.v16.i25.3187

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  32 in total

1.  Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy.

Authors:  J F Colombel; N Ferrari; H Debuysere; P Marteau; J P Gendre; B Bonaz; J C Soulé; R Modigliani; Y Touze; P Catala; C Libersa; F Broly
Journal:  Gastroenterology       Date:  2000-06       Impact factor: 22.682

2.  6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease.

Authors:  Marla C Dubinsky; Huiying Yang; Philip V Hassard; Ernest G Seidman; Lori Y Kam; Maria T Abreu; Stephan R Targan; Eric A Vasiliauskas
Journal:  Gastroenterology       Date:  2002-04       Impact factor: 22.682

Review 3.  Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications?

Authors:  Jenny E Higgs; Katherine Payne; Chris Roberts; William G Newman
Journal:  Pharmacogenomics       Date:  2010-02       Impact factor: 2.533

4.  Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide.

Authors:  P W Lowry; C L Franklin; A L Weaver; C L Szumlanski; D C Mays; E V Loftus; W J Tremaine; J J Lipsky; R M Weinshilboum; W J Sandborn
Journal:  Gut       Date:  2001-11       Impact factor: 23.059

5.  Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism.

Authors:  Matthias Schwab; Elke Schäffeler; Claudia Marx; Christine Fischer; Thomas Lang; Christoph Behrens; Michael Gregor; Michel Eichelbaum; Ulrich M Zanger; Bernd A Kaskas
Journal:  Pharmacogenetics       Date:  2002-08

6.  Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease.

Authors:  J Winter; A Walker; D Shapiro; D Gaffney; R J Spooner; P R Mills
Journal:  Aliment Pharmacol Ther       Date:  2004-09-15       Impact factor: 8.171

7.  Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease.

Authors:  R B Gearry; M L Barclay; M J Burt; J A Collett; B A Chapman; R L Roberts; M A Kennedy
Journal:  Aliment Pharmacol Ther       Date:  2003-08-15       Impact factor: 8.171

8.  Determination of thiopurine methyltransferase genotype or phenotype optimizes initial dosing of azathioprine for the treatment of Crohn's disease.

Authors:  Miguel Regueiro; Houssam Mardini
Journal:  J Clin Gastroenterol       Date:  2002-09       Impact factor: 3.062

9.  Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase).

Authors:  Anthony M Marinaki; Azhar Ansari; John A Duley; Monica Arenas; Satoshi Sumi; Cathryn M Lewis; El-Monsor Shobowale-Bakre; Emilia Escuredo; Lynette D Fairbanks; Jeremy D Sanderson
Journal:  Pharmacogenetics       Date:  2004-03

10.  Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy.

Authors:  Luc J J Derijks; Lennard P L Gilissen; Leopold G J B Engels; Laurens P Bos; Paul J Bus; Joseph J H M Lohman; Wouter L Curvers; Sander J H Van Deventer; Daniel W Hommes; Piet M Hooymans
Journal:  Ther Drug Monit       Date:  2004-06       Impact factor: 3.681

View more
  21 in total

Review 1.  Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease.

Authors:  Kara Bradford; David Q Shih
Journal:  World J Gastroenterol       Date:  2011-10-07       Impact factor: 5.742

2.  Does cardiology hold pharmacogenetics to an inconsistent standard? A comparison of evidence among recommendations.

Authors:  Jasmine A Luzum; Jason C Cheung
Journal:  Pharmacogenomics       Date:  2018-09-10       Impact factor: 2.533

Review 3.  Role of genetics in the diagnosis and prognosis of Crohn's disease.

Authors:  Epameinondas V Tsianos; Konstantinos H Katsanos; Vasileios E Tsianos
Journal:  World J Gastroenterol       Date:  2011-12-28       Impact factor: 5.742

Review 4.  Monitoring thiopurine metabolites in inflammatory bowel disease.

Authors:  Yago González-Lama; Javier P Gisbert
Journal:  Frontline Gastroenterol       Date:  2016-04-07

Review 5.  Attitudes of health care professionals toward pharmacogenetic testing.

Authors:  Nathalie K Zgheib; Thalia Arawi; Rami A Mahfouz; Ramzi Sabra
Journal:  Mol Diagn Ther       Date:  2011-04-01       Impact factor: 4.074

Review 6.  Clinical Utility of Biomarkers in IBD.

Authors:  Gerhard Rogler; Luc Biedermann
Journal:  Curr Gastroenterol Rep       Date:  2015-07

7.  Thiopurine-methyltransferase variants in inflammatory bowel disease: prevalence and toxicity in Brazilian patients.

Authors:  Ana Teresa P Carvalho; Barbara C Esberard; Renata S B Fróes; Davy C M Rapozo; Ana B Grinman; Tatiana A Simão; Juliana C V C Santos; Antonio José V Carneiro; Luis Felipe Ribeiro-Pinto; Heitor S P de Souza
Journal:  World J Gastroenterol       Date:  2014-03-28       Impact factor: 5.742

Review 8.  Thiopurine Therapy in Patients With Inflammatory Bowel Disease: A Focus on Metabolism and Pharmacogenetics.

Authors:  Ji Young Chang; Jae Hee Cheon
Journal:  Dig Dis Sci       Date:  2019-07-09       Impact factor: 3.487

9.  Association between thiopurine S-methyltransferase polymorphisms and thiopurine-induced adverse drug reactions in patients with inflammatory bowel disease: a meta-analysis.

Authors:  Yue-Ping Liu; Hai-Yan Wu; Xiang Yang; Han-Qing Xu; Yong-Chuan Li; Da-Chuan Shi; Jun-Fu Huang; Qing Huang; Wei-Ling Fu
Journal:  PLoS One       Date:  2015-03-23       Impact factor: 3.240

10.  Association between Thiopurine S-Methyltransferase Polymorphisms and Azathioprine-Induced Adverse Drug Reactions in Patients with Autoimmune Diseases: A Meta-Analysis.

Authors:  Yue-Ping Liu; Han-Qing Xu; Ming Li; Xiang Yang; Shu Yu; Wei-Ling Fu; Qing Huang
Journal:  PLoS One       Date:  2015-12-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.